Axa S.A. Raises Stake in argenx SE (NASDAQ:ARGX)

Axa S.A. boosted its holdings in shares of argenx SE (NASDAQ:ARGX) by 0.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 36,372 shares of the company’s stock after buying an additional 20 shares during the quarter. Axa S.A. owned 0.06% of argenx worth $15,641,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Blue Trust Inc. raised its holdings in shares of argenx by 620.0% during the second quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after purchasing an additional 62 shares during the last quarter. J.Safra Asset Management Corp raised its stake in shares of argenx by 590.0% during the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after buying an additional 59 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of argenx by 420.0% in the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after buying an additional 63 shares during the period. Mather Group LLC. purchased a new stake in shares of argenx in the first quarter worth about $38,000. Finally, Point72 Hong Kong Ltd acquired a new stake in argenx during the second quarter worth about $76,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ARGX has been the subject of a number of analyst reports. Stifel Nicolaus boosted their price target on argenx from $485.00 to $500.00 and gave the company a “buy” rating in a report on Monday, June 24th. Evercore ISI increased their price target on shares of argenx from $478.00 to $533.00 and gave the stock an “outperform” rating in a report on Friday, July 12th. Truist Financial lifted their price objective on shares of argenx from $480.00 to $540.00 and gave the company a “buy” rating in a report on Monday, July 22nd. Piper Sandler increased their target price on shares of argenx from $522.00 to $535.00 and gave the stock an “overweight” rating in a research note on Monday, June 24th. Finally, HC Wainwright raised their target price on argenx from $504.00 to $533.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Three research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $547.74.

argenx Trading Up 2.2 %

NASDAQ:ARGX opened at $536.11 on Friday. The company has a market cap of $31.86 billion, a P/E ratio of -94.72 and a beta of 0.62. argenx SE has a twelve month low of $327.73 and a twelve month high of $554.74. The company’s 50-day moving average price is $519.04 and its 200-day moving average price is $437.43.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, July 25th. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of ($0.89) by $1.34. The business had revenue of $489.43 million for the quarter, compared to analysts’ expectations of $436.66 million. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. During the same period in the previous year, the firm posted ($1.69) EPS. On average, analysts expect that argenx SE will post -0.37 earnings per share for the current year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.